ORKA (Oruka Therapeutics) OCF Margin %: 0.00% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ORKA Oruka Therapeutics Inc ORKA
14 GF Score
Price $92.45
! 3 Warning Signs
View Full Analysis

What is Oruka Therapeutics OCF Margin %?

Oruka Therapeutics ORKA +0.33% 14 OCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates ORKA with a GF Score™ of 14/100. The stock has 3 warning signs investors should review. Among 949 Biotechnology companies, Oruka Therapeutics ranks worse than 105373.97% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Oruka Therapeutics's Cash Flow from Operations for the three months ended in Mar. 2026 was $-23.58 Mil. Oruka Therapeutics's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Oruka Therapeutics's OCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Oruka Therapeutics's current OCF Yield % is -1.63%.

The historical rank and industry rank for Oruka Therapeutics's OCF Margin % or its related term are showing as below:


ORKA's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -66.52
* Ranked among companies with meaningful OCF Margin % only.

Oruka Therapeutics OCF Margin % Related Terms

Oruka Therapeutics OCF Margin % Historical Data

* Premium members only.

The historical data trend for Oruka Therapeutics's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oruka Therapeutics OCF Margin % Chart

Oruka Therapeutics Annual Data
Trend Dec24 Dec25
OCF Margin %
0.00 0.00

Oruka Therapeutics Quarterly Data
Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00
ORKA
14GF Score
Oruka Therapeutics Inc ORKA
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oruka Therapeutics OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Oruka Therapeutics's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-88.21/0
= %

Oruka Therapeutics's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-23.578/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Oruka Therapeutics (ORKA) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Oruka Therapeutics and its competitors. According to the industry distribution chart, Oruka Therapeutics ranks #999999 out of 949 companies in the Biotechnology industry.
Is Oruka Therapeutics' OCF Margin % too high?
Oruka Therapeutics' current OCF Margin % is 0.00%. Based on the distribution chart, Oruka Therapeutics ranks #999999 out of 949 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Oruka Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Oruka Therapeutics' OCF Margin % compare to DNTH and SRRK?
According to the Biotechnology industry distribution chart, Oruka Therapeutics ranks #999999 out of 949 companies for OCF Margin %. This places Oruka Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Oruka Therapeutics and its competitors. Oruka Therapeutics's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oruka Therapeutics stock overvalued right now?
Oruka Therapeutics (ORKA) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Oruka Therapeutics' overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Oruka Therapeutics (ORKA), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Oruka Therapeutics Business Description

Other Exchanges HQ1:Germany
Address 855 Oak Grove Avenue, Suite 100, Menlo Park, CA, USA, 94025
Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.
14GF Score

Get the complete analysis for ORKA

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$92.45
Price